Sir, 1. What are the indications for which you have used apremilast? Dr. Uday Khopkar: The most common indication for which I have used apremilast is psoriasis.
Among the different types of psoriasis, I have used in guttate or eruptive psoriasis, unstable psoriasis (though not the pustular type), and chronic plaque psoriasis. [1] I have also used apremilast in a few patients having psoriasis with concomitant atopic diathesis or atopic dermatitis. However, its efficacy in atopic dermatitis is not as much as in psoriasis.
The other indications for which apremilast has been used are shown in Box 1. Psoriatic arthritis [1, 2] Alopecia areata [1] Atopic dermatitis [3] Behcet's disease [3] Hidradenitis suppurativa [3] Nail, scalp, palmoplantar psoriasis [3] Discoid lupus erythematosus However, one must be extra cautious and monitor the patients' laboratory parameters (complete hemogram and liver and renal function tests) when combining these drugs.
Box 2 provides the list of combination treatments of apremilast with other drugs described in literature.
8. How would you rate the onset of action of apremilast in comparison to methotrexate, cyclosporine, and acitretin?
Dr. Uday Khopkar:
• In unstable plaque psoriasis from rapid to slow onset of action, I use apremilast with extreme caution in geriatric population due to the higher incidence of gastrointestinal side effects and their proneness for water and electrolyte disturbance. I have also noticed that apremilast in the regular adult dose is not tolerated well by women of all age groups. Hence, I try to avoid using this drug in the regular dosage in female patients. I have no experience of using apremilast in the pediatric age group as of now.
What are the drug interactions to be kept in mind?
Dr. Uday Khopkar: When apremilast is coadministered with strong inducers of CYP3A4 enzyme (rifampicin, carbamazepine, phenytoin, and phenobarbitone), it reduces clinical response in patients of psoriasis. Acitretin [2] Cyclosporine Infliximab Etanercept Ustekinumab [2] Adalimumab Secukinumab [2] Gastrointestinal system Nausea [4] Reduced appetite Vomiting [4] Dyspepsia Diarrhea [4] Increased frequency of bowel movements Abdominal spasm [4] Gastroesophageal reflux disease Weight loss Respiratory system Cough [4] Nasopharyngitis Upper respiratory tract infection Bronchitis Central Nervous system Insomnia Migraine Low mood [4] Depression Dizziness [4] Tension headache Headache [4] Cutaneous In some patients, who do not tolerate even that dose, and are ready to give another try, I build up the dose steadily as 10 mg once daily for a month and then only increase to 20 and then 30 over 2 months.
However, more studies on the use of lower doses of apremilast for our population need to be done before we can conclude on its efficacy and safety.
The current recommended dosage schedule is shown in Table 2 .
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